Zai Lab (ZLAB) FCF Margin (2019 - 2026)

Zai Lab (ZLAB) posted FCF Margin of 13.16% for Q1 2026, up 37.12% sequentially from 20.92% in Q4 2025, and up 4622.0% YoY from 0.28% in Q1 2025.

Zai Lab (ZLAB) FCF Margin (2019 - 2026) Analysis & Trends

Zai Lab has reported FCF Margin for 8 years, with the latest figure at 13.16% in Q1 2026.

Quarterly FCF Margin rose 4622.0% year-over-year to 13.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.99% (up 2206.0% YoY) and the FY2025 annual result came in at 34.53%, up 2074.0% from the prior year.
FCF Margin improved to 13.16% in Q1 2026 per ZLAB's latest filing, from 20.92% in the prior quarter.
Over five years, FCF Margin peaked at 13.16% in Q1 2026 and troughed at 231.16% in Q3 2022.
A 5-year average of 83.11% and a median of 59.38% in 2025 frame the typical range for FCF Margin.
The sharpest annual moves came in 2022 and 2024: FCF Margin jumped 64421 bps in 2022, then tumbled 3052 bps in 2024.
Over 5 years, FCF Margin stood at 181.63% in 2022, then surged by 87 bps to 23.0% in 2023, then sank by 133 bps to 53.52% in 2024, then soared by 61 bps to 20.92% in 2025, then jumped by 37 bps to 13.16% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 13.16%, 20.92%, and 30.19% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	Zai Lab	2.91 Bn	2.20 Bn	58.15 Mn	-60.87%

Download Data